UY36020A - ALFA INHIBIN ANTIGEN, ALFA INHIBINE CODING GENE, FUSION PROTEIN CODING GENE, ALFA INHIBINE ANTIGEN OBTAINING PROCESS, ANTIGEN COMPOSITION, ALFA INHIBIN ANTIGEN USE AND ANTIGEN COMPOSITION - Google Patents

ALFA INHIBIN ANTIGEN, ALFA INHIBINE CODING GENE, FUSION PROTEIN CODING GENE, ALFA INHIBINE ANTIGEN OBTAINING PROCESS, ANTIGEN COMPOSITION, ALFA INHIBIN ANTIGEN USE AND ANTIGEN COMPOSITION

Info

Publication number
UY36020A
UY36020A UY0001036020A UY36020A UY36020A UY 36020 A UY36020 A UY 36020A UY 0001036020 A UY0001036020 A UY 0001036020A UY 36020 A UY36020 A UY 36020A UY 36020 A UY36020 A UY 36020A
Authority
UY
Uruguay
Prior art keywords
antigen
alfa
inhibin
inhibine
coding gene
Prior art date
Application number
UY0001036020A
Other languages
Spanish (es)
Inventor
Celso Raul Romero Ramos
Miryam Marroquin Quelopana
Original Assignee
Ouro Fino Saúde Animal Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ouro Fino Saúde Animal Ltda filed Critical Ouro Fino Saúde Animal Ltda
Publication of UY36020A publication Critical patent/UY36020A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una proteína inhibina alfa modificada, sus fragmentos antigénicos y proteína de fusión comprendiendo la misma, así como a su proceso de producción e a sus usos; a una composición antigénica comprendiendo los mismos, y a su uso en el aumento de la ovulación de animales, especialmente mamíferos y aves. La invención se fundamenta en la modificación de la secuencia madura de la subunidad alfa de la inhibina de Bos taurus, e n el segmento de la extremidad C-terminal que pasa a tener las dos regiones más inmunogénicas en ese segmento.The invention relates to a modified alpha inhibin protein, its antigenic fragments and fusion protein comprising the same, as well as its production process and its uses; to an antigenic composition comprising the same, and to its use in the increase of ovulation of animals, especially mammals and birds. The invention is based on the modification of the mature sequence of the alpha subunit of Bos taurus inhibin, in the segment of the C-terminal limb that happens to have the two most immunogenic regions in that segment.

UY0001036020A 2014-03-07 2015-03-05 ALFA INHIBIN ANTIGEN, ALFA INHIBINE CODING GENE, FUSION PROTEIN CODING GENE, ALFA INHIBINE ANTIGEN OBTAINING PROCESS, ANTIGEN COMPOSITION, ALFA INHIBIN ANTIGEN USE AND ANTIGEN COMPOSITION UY36020A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102014005376A BR102014005376A2 (en) 2014-03-07 2014-03-07 inhibin alpha antigen, inhibin alpha coding gene, fusion protein encoding gene, process of obtaining inhibin alpha antigen, antigenic composition, use of inhibin alpha antigen, and use of antigenic composition

Publications (1)

Publication Number Publication Date
UY36020A true UY36020A (en) 2015-09-30

Family

ID=54054284

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036020A UY36020A (en) 2014-03-07 2015-03-05 ALFA INHIBIN ANTIGEN, ALFA INHIBINE CODING GENE, FUSION PROTEIN CODING GENE, ALFA INHIBINE ANTIGEN OBTAINING PROCESS, ANTIGEN COMPOSITION, ALFA INHIBIN ANTIGEN USE AND ANTIGEN COMPOSITION

Country Status (4)

Country Link
AR (1) AR099671A1 (en)
BR (1) BR102014005376A2 (en)
UY (1) UY36020A (en)
WO (1) WO2015131254A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
KR940004077B1 (en) * 1985-04-18 1994-05-11 바이오테크놀로지 오스트레일리아 프로프라이어터리 리밋티드 Recombinantinhbin
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US4864019A (en) * 1985-11-08 1989-09-05 The Salk Institute For Biological Studies Antibodies to inhibin and conjugates produced therefrom
ES2065673T3 (en) * 1990-01-08 1995-02-16 Genentech Inc PROCEDURE TO INCREASE FERTILITY IN FEMALES.
US20040220098A1 (en) * 1994-02-28 2004-11-04 Satterlee Daniel G. Inhibin compositions and methods of enhancing fertility and growth
PT804219E (en) * 1994-02-28 2002-12-31 Agritech Technologies Ltd INIBINE COMPOSITIONS AND METHODS FOR THEIR USE
JPH07238097A (en) * 1994-09-07 1995-09-12 Masao Igarashi Igg antibody comprising inhibin as antigen
JP2899534B2 (en) * 1994-12-09 1999-06-02 全国農業協同組合連合会 Method of inducing superovulation in cattle
JP2006523180A (en) * 2002-11-07 2006-10-12 アグリテック テクノロジー リミテッド Novel inhibin-related multi-antigen peptide composition that promotes productivity in birds
BRPI0506043A (en) * 2005-07-12 2007-03-13 Univ Fed Do Rio Grande Do Sul animal evaluation and selection process
CN101407781A (en) * 2008-12-01 2009-04-15 华中农业大学 Inhibin DNA vaccine capable of improving animal fertility, and preparation and use thereof

Also Published As

Publication number Publication date
AR099671A1 (en) 2016-08-10
WO2015131254A1 (en) 2015-09-11
BR102014005376A2 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
CO2019010503A2 (en) Custom immunogenic peptide identification platform
CO2017009061A2 (en) Variant polypeptides of the immunoglobulin degradation enzyme g of s. pyogenes
CL2021002994A1 (en) Novel antibodies that specifically bind to Zika virus epitopes and their uses. (divisional application no. 201900067)
CL2016001968A1 (en) Interleukin-2 fusion proteins and uses thereof
CO2018011804A2 (en) Flt3 chimeric receptors and methods of use thereof
CO2018009995A2 (en) Binding proteins and methods of use thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CO2017000507A2 (en) Chimeric bcma antigen receptor
CO2017000510A2 (en) Car constructs
CO2017009060A2 (en) Hybrid polypeptide of the immunoglobulin degradation enzyme g of s. pyogenes and immunoglobulin g degradation enzyme of streptococcus equi ssp. zooepidemicus
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
CL2017000651A1 (en) Anti-glucagon antibodies and their uses
ECSP18096095A (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM
BR112019010275A2 (en) recombinant adenovirus, composition, use of adenovirus or composition, method of inducing an immune response in a patient, and non-human simian adenovirus
BR112016028891A2 (en) seed train processes and uses
UY36021A (en) FC MULTIMÈRIC PROTEINS
CL2016000538A1 (en) Compound comprising the h and klh balloon protein, compositions of a carbohydrate vaccine for the induction of immune responses and uses thereof
CO2020009402A2 (en) Fc il-22 fusion proteins and methods of use
UY36006A (en) USPA2 PROTEIN CONSTRUCTIONS AND USES OF THE SAME.
CL2017000053A1 (en) Β-protofibril binding antibodies
PE20171076A1 (en) COMPOSITION CONTAINING CHITIN AND DIGERIBLE PROTEINS
EA201692279A1 (en) METHOD FOR REDUCING IMMUNOGENIC PROTEIN AND PEPTIDE
PE20151978A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING A PEPTIDIC COMPONENT WITH ANT-INFLAMMATORY PROPERTIES AND USES OF THE SAME
CL2019002323A1 (en) Il-13ra2 antibody and its use.
CR20160593A (en) Interferon alpha and omega antibody antagonists.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220610